Garuda Therapeutics seeks to create a world that eliminates the dependency on donor or patient cells for blood stem cell transplants. Garuda's platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible and transgene-free blood stem cell therapies. Like bone marrow transplants, Garuda's technology could provide potentially curative therapies for more than 70 diseases.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $184M
Investors 2
| Date | Name | Website |
| 24.04.2022 | Aisling Ca... | aislingcap... |
| - | OrbiMed | orbimed.co... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 12.03.2025 | Series A | $50M | - |
| 07.02.2023 | Series B | $62M | Aisling Ca... |
| 23.09.2021 | Series A | $72M | - |
Mentions in press and media 13
| Date | Title | Description |
| 13.03.2025 | Garuda Therapeutics Secures $50 Million to Revolutionize Blood Stem Cell Treatments | In the world of biotechnology, innovation is the lifeblood. Garuda Therapeutics, a company based in Cambridge, Massachusetts, has just taken a bold step forward. They’ve secured $50 million in Series A-1 funding. This financial boost is not... |
| 12.03.2025 | Shift Bioscience announces key appointments to advance rejuvenation therapeutics pipeline | Jill Reckless (CEO, RxCelerate) appointed as Translation Advisor Laurence Reid joins as Non-Executive Director, previously Decibel Therapeutics, Warp Drive Bio, Alnylam, and Millennium Pharmaceuticals Cambridge, UK, 12 March 2025: Shift Bio... |
| 12.03.2025 | Garuda Therapeutics: $50 Million (Series A-1) Secured For Advancing Blood Stem Cell Therapies | Garuda Therapeutics – a biotechnology company creating off-the-shelf and HSC therapies for a multitude of blood disorders – announced the completion of an approximately $50 million Series A-1 funding round. Investors included OrbiMed, North... |
| 04.03.2025 | Garuda Therapeutics Closes $50M Series A-1 Financing | Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding. Backers included OrbiMed, Northpond Ventures, Cormorant Asset Management, Kyowa Kirin Co., Ltd., a Japan-based Gl... |
| 13.02.2023 | Drone start-up Garuda raises $22 mn in series A funding from SphitiCap | Drone manufacturer Garuda Aerospace has raised $22 million in funding led by SphitiCap, which invested $12 million in the company. The series A funding round also saw participation from investors and HNIs from India, UAE and Singapore. Garu... |
| 07.02.2023 | Garuda Therapeutics Secures $62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform | CAMBRIDGE, MA.– Garuda Therapeutics (Garuda), a company creating off-the-shelf, durable blood stem cell-based cellular therapies, today announced a $62 million Series B financing led by Northpond Ventures, OrbiMed Advisors, Cormorant Asset ... |
| 07.02.2023 | Garuda Therapeutics Raises $62M in Series B Financing | Garuda Therapeutics, a Cambridge, MA-based developer of durable blood stem cell-based cellular therapies, raised $62M in Series B funding. The round, which brought the total amount of funding to $134M, was led by Northpond Ventures, OrbiM... |
| 07.02.2023 | Garuda Therapeutics Scoops Up $62M Series B | CAMBRIDGE, MA, Garuda Therapeutics, a company creating off-the-shelf, durable blood stem cell-based cellular therapies, today announced a $62 million Series B financing. >> Click here for more funding data on Garuda Therapeutics &... |
| 24.09.2021 | Garuda Therapeutics Raises $72M in Series A Financing | Garuda Therapeutics, a Cambridge, Mass.-based company creating off-the-shelf, durable blood stem cell therapies, raised $72m in Series A financing. The round was led by Aisling Capital, Northpond Ventures and Orbimed, supported by Cormorant... |
| 23.09.2021 | Garuda Therapeutics Launches With $72M | CAMBRIDGE, MA, Garuda Therapeutics launched today with an oversubscribed $72 million Series A financing round. >> Click here for more funding data on Garuda Therapeutics >> To export Garuda Therapeutics funding data to PDF a... |
Show more